nature portfolio

Li Wang, Zhengwang Wu, Gang Li

Last updated by author(s): 2022-09-20

Corresponding author(s):

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

Statistics

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🖸 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	••••••••••••••••••••••••••••••••••••••
O ^A	full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) ND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection Our pipeline is available at: https://github.com/iBEAT-V2/iBEAT-V2.0-Docker.

Data analysis The ITK-Snap (http://www.itksnap.org/pmwiki/pmwiki.php) is used for checking the tissue segmentation performance and visualizing the tissue For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets

- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The datasets we used are publicly available, including, i) BCP (https://nda.nih.gov/edit_collection.html?id=2848; ii) dHCP (http://www.developingconnectome.org/datarelease/second-data-release/). iii) MSMR-6 (https://iseg2019.web.unc.edu/data/)

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender	n/a			
Population characteristics	n/a			
Recruitment	n/a			
Ethics oversight	University of North Carolina at Chapel Hill			
Note that full information on the approval of the study protocol must also be provided in the manuscript				

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

OLife sciences

OBehavioural & social sciences

C Ecological, evolutionary & environmental sciences

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We used the publicly available brain MR image datasets. The sample sizes are fixed when the data are released.
Data exclusions	No data is excluded.
Replication	The images are processed by our pipeline and the replication is successful.
Randomization	n/a
Blinding	n/a

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Studv description	
Research sample	
Sampling strategy	
Data collection	
Timing	
Data exclusions	
Non-participation	
Randomization	

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	
Research sample	
Sampling strategy	
Data collection	
Timing and spatial scale	
Data exclusions	
Reproducibility	
Randomization	

Blinding			
		_	_
Did the study involve field	work?	OYes	ONo

Field work, collection and transport

Field conditions	
Location	
Access & import/export	
Disturbance	

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Methods	
n/a	Involved in the study	n/a	Involved in the study
	Antibodies		ChIP-seq
(OEukaryotic cell lines	(Clow cytometry
	Palaeontology and archaeology		MRI-based neuroimaging
(OAnimals and other organisms		
	OClinical data		
(ODual use research of concern		

Antibodies

Antibodies used	
Validation	

Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research				
Cell line source(s)				
Authentication				
Mvcoplasma contamination				
Commonly misidentified lines (See ICLAC register)				

Palaeontology and Archaeology

Specimen provenance			
Specimen deposition			
Dating methods			
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.			
Ethics oversight			

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

Laboratorv animals	
Wild animals	
Reporting on sex	
Field-collected samples	
Ethics oversight	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about clinical studies

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration	
Study protocol	
Data collection	
Outcomes	

Dual use research of concern

Policy information about dual use research of concern

Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

- No
 - Yes OOPublic health
 - ONational security
 - OCrops and/or livestock
 - **O**Ecosystems
 - OAny other significant area

Experiments of concern

Yes

Does the work involve any of these experiments of concern:

- No
 - ODemonstrate how to render a vaccine ineffective
 - OConfer resistance to therapeutically useful antibiotics or antiviral agents
 - OEnhance the virulence of a pathogen or render a nonpathogen virulent
 - OIncrease transmissibility of a pathogen

 - OEnable evasion of diagnostic/detection modalities
 - OEnable the weaponization of a biological agent or toxin
 - OAny other potentially harmful combination of experiments and agents

ChIP-seq

Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as GEO.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links	
May remain private before publication	
Files in database submission	
Genome browser session (e.g. UCSC)	

Methodology

Replicates	
Seauencing depth	
Antibodies	
Peak calling parameters	
Data qualitv	
Software	

Flow Cytometry

Plots

Confirm that:

The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation		
Instrument		
Software		
Cell population abundance		
Gating strategy		
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.		

Magnetic resonance imaging

Experimental design Design type	
Design specifications	
Behavioral performance measures	
Acquisition	
Imaging type(s)	
Field strength	
Sequence & imaging parameters	
Area of acquisition	
Diffusion MRI OUsed	ONot used
Preprocessing	
Preprocessing software	
Normalization)
Normalization template	
Noise and artifact removal)
Volume censoring)
Statistical modeling & inference	2
Model type and settings	
Effect(s) tested	
Specify type of analysis: OWhole	brain OROI-based OBoth
Statistic type for inference (See Eklund et al. 2016)	
Correction)

Models & analysis

n/a Involved in the study

Functional and/or effective connectivity

Graph analysis

Multivariate modeling or predictive analysis

Functional and/or effective connectivity

Graph analysis

Multivariate modeling and predictive analysis

This checklist template is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

